A detailed history of Two Sigma Investments, LP transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 1,052,398 shares of ZNTL stock, worth $3.95 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,052,398
Previous 244,995 329.56%
Holding current value
$3.95 Million
Previous $3.86 Million 11.47%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.09 - $16.13 $3.3 Million - $13 Million
807,403 Added 329.56%
1,052,398 $4.3 Million
Q1 2024

May 15, 2024

BUY
$10.83 - $16.49 $2.65 Million - $4.04 Million
244,995 New
244,995 $3.86 Million
Q3 2023

Nov 14, 2023

BUY
$19.63 - $28.29 $1.82 Million - $2.62 Million
92,729 Added 555.26%
109,429 $2.2 Million
Q2 2023

Aug 14, 2023

BUY
$17.41 - $30.05 $290,747 - $501,835
16,700 New
16,700 $471,000
Q2 2022

Aug 15, 2022

SELL
$17.91 - $52.25 $1.69 Million - $4.94 Million
-94,502 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$41.58 - $80.89 $3.34 Million - $6.5 Million
80,349 Added 567.72%
94,502 $4.36 Million
Q4 2021

Feb 14, 2022

SELL
$66.92 - $84.79 $9.69 Million - $12.3 Million
-144,823 Reduced 91.1%
14,153 $1.19 Million
Q3 2021

Nov 15, 2021

BUY
$46.83 - $73.5 $1.41 Million - $2.21 Million
30,105 Added 23.36%
158,976 $10.6 Million
Q2 2021

Aug 16, 2021

BUY
$37.41 - $62.25 $4.82 Million - $8.02 Million
128,871 New
128,871 $6.86 Million
Q1 2021

May 17, 2021

SELL
$35.69 - $52.72 $2.04 Million - $3.01 Million
-57,031 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$31.71 - $57.97 $1.81 Million - $3.31 Million
57,031 New
57,031 $2.96 Million

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $214M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.